| 11/28/2025 17:00 |
The 149th (interim period) Business Report |
| 10/30/2025 16:30 |
Semi-annual Securities Report (The semi-annual of 149th Business Term) for The Six-month Period Ended September 30, 2025 |
| 10/30/2025 15:40 |
Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS) |
| 10/30/2025 15:40 |
Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2025 (IFRS, Consolidated) |
| 10/01/2025 22:00 |
Takeda Provides Update on Cell Therapy Research |
| 09/25/2025 08:45 |
Information About General Reserve and Other Voluntary Reserves |
| 09/08/2025 16:00 |
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 |
| 07/31/2025 13:00 |
Statement on Inadvertent Abstract Disclosure for Opevorexton (TAK-861) by World Sleep Congress |
| 07/30/2025 15:30 |
Earnings Report (Kessan Tanshin) for the Three-month Period Ended June 30, 2025 (IFRS, Consolidated) |
| 07/14/2025 16:00 |
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 |
| 07/09/2025 15:30 |
Corporate Governance Report 2025/07/09 |
| 07/08/2025 16:00 |
Takeda Completes Disposal of Treasury Shares under the LTIP for Company Group Employees Outside of Japan with Partial Forfeiture |
| 07/01/2025 00:30 |
2025 ANNUAL INTEGRATED REPORT |
| 06/25/2025 17:00 |
Annual Securities Report From April 1, 2024 to March 31, 2025 (The 148th Fiscal Year) |
| 06/25/2025 16:00 |
Takeda Announces New Assignments of Directors |
| 06/10/2025 16:00 |
Notice Concerning Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan |
| 06/07/2025 08:00 |
Statement from the Chair of the Board of Takeda, in Response to ISS's Voting Recommendations Ahead of the 149th Annual General Meeting of Shareholder |
| 06/02/2025 16:00 |
Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan |
| 06/02/2025 08:45 |
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide |
| 05/29/2025 08:00 |
TAKEDA's EXECUTIVE COMPENSATION OVERVIEW |
| 05/29/2025 08:00 |
Message from Christophe Weber, President & CEO |
| 05/29/2025 08:00 |
Other items which are provided electronically for the 149th Ordinary General Meeting of Shareholders |
| 05/29/2025 08:00 |
Notice of Convocation of the 149th Ordinary General Meeting of Shareholders and Meeting Materials |
| 05/08/2025 16:00 |
Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2025 |
| 05/08/2025 15:30 |
Earnings Report (Kessan Tanshin) for the Fiscal Year Ended March 31, 2025 (IFRS, Consolidated) |
| 04/22/2025 15:30 |
Takeda Announces Completion of Acquisition of Own Shares |
| 04/01/2025 15:30 |
Takeda Provides Update on Status of Acquisition of Own Shares |
| 03/26/2025 18:30 |
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting |
| 03/03/2025 20:45 |
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera |
| 03/03/2025 15:30 |
Takeda Provides Update on Status of Acquisition of Own Shares |
| 01/30/2025 16:00 |
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 |
| 01/30/2025 15:30 |
Takeda Provides Update on Soticlestat (TAK-935) |
| 01/30/2025 15:30 |
Takeda Announces Acquisition of Own Shares |
| 01/30/2025 15:30 |
Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS) |
| 01/30/2025 15:30 |
Earnings Report (Kessan Tanshin) for the Nine-month Period Ended December 31, 2024 (IFRS, Consolidated) |
| 12/13/2024 08:30 |
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple TA |
